BodyNCT07409090
Micro-Coring® for the Treatment of Skin Laxity of the Knees
A study testing Micro-Coring in people with Body and Knees, run by Cytrellis Biosystems, Inc. at 1 site in United States.
Trial summary
Early, informal clinical experience suggests that Micro-Coring may help improve skin quality in certain body areas, such as the knees. However, this body region has not yet been formally studied. Read more about this study
- Who is it for?
- Ages 22 to 70 yearsHealthy volunteers can take part
- What is being tested?
- Micro-Coring
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Feb 2026to Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Male or female age 22 to 70
- With lax skin over one or both knees, physician discretion
- Able to provide written informed consent, understand and willing to comply with all study related procedures and follow-up visits
- Fitzpatrick Skin Type I to VI as evaluated by the Investigator
Who cannot join
- Pregnant women or nursing mothers
- Body mass index > 30 · Patients with dermatosis, open wounds, sores, or irritated skin in the treatment area
- Patients with allergy to stainless steel or to topical, oral, or injected medications or preparations that may be used during the procedure, such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine
- Patients with a history or presence of any clinically significant bleeding disorder
- Patients with dermatological or autoimmune conditions that may affect the treatment outcome; these may include, but are not limited to: actinic keratosis, raised nevi, rosacea, melasma, active acne, cutaneous papules/nodules, active inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, acute inflammatory phase of scleroderma, rheumatoid arthritis, eczema, psoriasis, allergic dermatitis, collagen disorders, or lupus
- Patients with systemic infections or acute local skin infections (as Hepatitis disorders type A, B, C, D, E or F or HIV infection)
Show all 16Show fewer
- Patients who are on a high dose of anti-coagulants or blood-thinning substances, e.g., aspirin > 150 mg/day, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, heparin, acetylsalicylic acid during the previous fourteen (14) days
- Patients who are on courses of chemotherapy, high-dose corticosteroid use, or radiation in the treatment area
- Patients with have undergone surgery of the treatment area within last twelve (12) months, or have any scars less than twelve (12) months old in the treatment area
- Patients who have undergone injections of dermal fillers, fat, or botulinum toxin, as well as any minimally invasive/invasive skin treatment in the treatment area during the previous six (6) months
- During the study time frame, unwilling to refrain from receiving these following aesthetic treatments within the same body region: toxin, filler, any skin resurfacing (laser, RF, ultrasound, microneedling, etc.);
- Are currently enrolled in, or have overlapping participation in, another clinical trial outside of Cytrellis that includes treatment to the study area.
- Unwilling to have photography taken for the study purpose
- Any physical or psychological factors, in the judgment of the study investigator, may prevent subject from adhering to the study requirement correctly.
- History of keloid formation or hypertrophic scarring
- Excessive sun exposure and use of tanning beds or tanning creams within 30 days prior to treatment and for the duration of the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Laser & Skin Surgery Center of Northern California
Sacramento, California, 95816
About this study
Official title: Evaluation of Micro-Coring® Technology for the Treatment of Skin Laxity of the Knees: A Prospective, Multi-Center Clinical Study
Early, informal clinical experience suggests that Micro-Coring may help improve skin quality in certain body areas, such as the knees. However, this body region has not yet been formally studied. Additional clinical evaluation is needed to better understand healing, potential side effects, patient experience, ease of use, and optimal treatment settings for body sites. This is especially important because body skin differs from facial skin in thickness, blood supply, movement, and mechanical stress, which may affect both safety and healing outcomes.
- Being tested
- Micro-Coring
- Keywords
- Micro-Coring, Body Coring, ellacor
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Micro-CoringDevice
Also called ellacor
Non-thermal device
| Study group | Role | What they receive |
|---|---|---|
| Micro-Coring on the knees | Other | ellacor as the micro-coring intervention Receives: Device: Micro-Coring |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correct identification of before and after treatment photos
The baseline photos (before) taken before the procedure, and 90-day post procedure visit photos (after) are randomized and presented to a panel of three blinded photographic evaluators. Study success is defined as 75% subjects or more show an improvement as agreed upon by a least two out of three evaluators.
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Feb 2026
- Study start2 Feb 2026
- Primary completionJun 2026 (estimated)
- Study completionAug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for BodyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cytrellis Biosystems, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07409090
- Sponsor's protocol ID
- TP-00460
- Status last verified
- Jan 2026
- First submitted
- 2 Feb 2026
- Last updated
- 13 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Micro-Coring® Technology for the Treatment of Skin Laxity of the Knees: A Prospective, Multi-Center Clinical Study
- ClinicalTrials.gov ID
- NCT07409090
- Acronym / sponsor ID
- TP-00460
- Keywords
- Micro-Coring, Body Coring, ellacor
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- Cytrellis Biosystems, Inc.Industry (pharma, biotech, devices)
- Study start
- 2 Feb 2026 (actual)
- Primary completion
- Jun 2026 (estimated)
- Study completion
- Aug 2026 (estimated)
- First posted
- 13 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Early, informal clinical experience suggests that Micro-Coring may help improve skin quality in certain body areas, such as the knees. However, this body region has not yet been formally studied. Additional clinical evaluation is needed to better understand healing, potential side effects, patient experience, ease of use, and optimal treatment settings for body sites. This is especially important because body skin differs from facial skin in thickness, blood supply, movement, and mechanical stress, which may affect both safety and healing outcomes.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Micro-Coring on the knees | Other | Device: Micro-Coringellacor as the micro-coring intervention |
Who may qualify
- Ages
- 22 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Male or female age 22 to 70
- With lax skin over one or both knees, physician discretion
- Able to provide written informed consent, understand and willing to comply with all study related procedures and follow-up visits
- Fitzpatrick Skin Type I to VI as evaluated by the Investigator
Key exclusion criteria (16 listed)
- Pregnant women or nursing mothers
- Body mass index > 30 · Patients with dermatosis, open wounds, sores, or irritated skin in the treatment area
- Patients with allergy to stainless steel or to topical, oral, or injected medications or preparations that may be used during the procedure, such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine
- Patients with a history or presence of any clinically significant bleeding disorder
- Patients with dermatological or autoimmune conditions that may affect the treatment outcome; these may include, but are not limited to: actinic keratosis, raised nevi, rosacea, melasma, active acne, cutaneous papules/nodules, active inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, acute inflammatory phase of scleroderma, rheumatoid arthritis, eczema, psoriasis, allergic dermatitis, collagen disorders, or lupus
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Micro-CoringAlso: ellacorNon-thermal device | Device | Micro-Coring on the knees |
Primary outcome
Correct identification of before and after treatment photos
Time frame: 90 days
The baseline photos (before) taken before the procedure, and 90-day post procedure visit photos (after) are randomized and presented to a panel of three blinded photographic evaluators. Study success is defined as 75% subjects or more show an improvement as agreed upon by a least two out of three evaluators.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Body
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
RecruitingPhase 2
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Micro-Coring in people with Body and Knees, run by Cytrellis Biosystems, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 13 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correct identification of before and after treatment photos (time frame: 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2026.